NVO Dec 2024 85.000 put
| Previous close | 1.0500 |
| Open | 1.0700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 85.00 |
| Expiry date | 2024-12-20 |
| Day's range | 1.0500 - 1.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
BloombergInvestors Pile Into Amgen in Search of Next Obesity Drug Payout
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeFrance’s Macron Calls for Reset of Economic Ties With ChinaTreasury Rally Risks Running Into a $125 Billion Brick WallXi Begins Europe Tour in Paris as Macron Seeks to Reset TiesThe shares sur
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insider MonkeyNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]
